Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): Final report

Hsu, Chiun; Yang, Tsung‐Ming; Toh, H.; Rs, Epstein; Hsiao, L.; Lin, Zilan; Cheng, Ann‐Lii

doi:10.1200/jco.2008.26.15_suppl.4603

Cited by 15 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results should be interpreted with caution because a sorafenib-alone arm was not included and high incidence of adverse events related to doxorubicin was noted. Many small-scale trials of combining MTT with cytotoxic chemotherapy have been reported [385][386][387][388][389]. However, the treatment efficacy in terms of tumor response rate and patient survival were similar to those reported for the cytotoxic regimens alone (Table 3) [372,[375][376][377][378][379][380][381][382].…”

Section: Future Directionsmentioning

confidence: 64%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

Introduction The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on the management of hepatocellular carcinoma (HCC) in December 2008 to develop consensus recommendations. Methods The working party consisted of expert hepatologist, hepatobiliary surgeon, radiologist, and oncologist from Asian-Pacific region, who were requested to make drafts prior to the consensus meeting held at Bali, Indonesia on 4 December 2008. The quality of existing evidence and strength of recommendations were ranked from 1 (highest) to 5 (lowest) and from A (strongest) to D (weakest), respectively, according to the Oxford system of evidence-based approach for developing the consensus statements. 123Hepatol Int (2010) 4: 439-474 DOI 10.1007/s12072-010-9165-7 Results Participants of the consensus meeting assessed the quality of cited studies and assigned grades to the recommendation statements. Finalized recommendations were presented at the fourth APASL single topic conference on viral-related HCC at Bali, Indonesia and approved by the participants of the conference.

show abstract

Section: Future Directionsmentioning

confidence: 64%

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

et al. 2010

View full text Add to dashboard Cite

show abstract

“…1,7,[73][74][75][76][77][78] The cancer cell has been the only target of anticancer therapy for more than 50 years. However, the cancer cell is genetically unstable, and mutations accumulate.…”

Section: Clinical Trials Of Antiangiogenic Agents In Patients With Hccmentioning

confidence: 99%

Vascular endothelial growth factor in the management of hepatocellular carcinoma

Kaseb

Hanbali

Cotant

et al. 2009

Cancer

110

View full text Add to dashboard Cite

The consumption of antidepressants, especially selective serotonine reuptake inhibitors (SSRI) has been increasing. Because a large fraction of the population is exposed, even a small excess of risk with respect to cancer should be considered. We carried out a record linkage study in Finland utilizing nationwide databases of reimbursed medication and cancer. The study population included all antidepressant drug (AD) users in Finland who had purchased at least 1 prescription between 1998 and 2005, and who had no cancer diagnosis at the date of first purchase. A control population without AD usage (matched by age and sex) was also included. Data consisted of 418,588 pairs of individuals that cumulated 3.3 million person‐years with an average of 4.0 years of follow‐up. 19,365 cancer cases were observed. The most frequent cancers were breast, prostate, lung, colon, and brain cancer. In general, only few associations between the utilization of AD and cancer could be detected. Over four years exposure to AD showed a weak association with increased colon and breast cancer incidence, which could have been caused by bias. As conclusion, no clear evidence of neither beneficial nor harmful association between usage of antidepressant and cancer was found.

show abstract

“…One, a phase II study, will compare bevacizumab and erlotinib versus sorafenib alone in a similar population as in the SHARP study, and the second, a phase III study, will compare erlotinib and sorafenib versus sorafenib alone. The safety and efficacy of bevacizumab and erlotinib is also being investigated in an ongoing study in Asian patients with advanced HCC (77). A recent interim analysis of safety data from this trial reported that, of the 51 enrolled patients, 2 patients had confirmed partial responses and 1 patient with an unconfirmed partial response remained on treatment.…”

Section: Monotherapy and Combination Therapymentioning

confidence: 99%

“…Brivanib has shown activity in mouse models of human HCC (77). Interim analyses from a study of single-agent brivanib as first-and second-line therapy showed that, in a largely Asian population of 55 patients with advanced HCC, first-line treatment with brivanib was associated with a median time to progression of 2.8 months, with a disease control rate of 60% (47 evaluable patients) and median OS of 10 months (79).…”

Section: Monotherapy and Combination Therapymentioning

confidence: 99%

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

Finn

2010

Clinical Cancer Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), once considered an orphan disease in the West, has become a global health concern. It is the third leading cause of cancer death worldwide, and its incidence continues to increase. Historically, the development of new systemic agents for advanced HCC has been lacking despite no clear benefit with traditional cytotoxic therapies. Although two randomized studies with sorafenib for the treatment of HCC patients have recently been completed, survival benefits have been modest and highlight the unmet medical need among patients with HCC. Given the clear need, clinical development of novel systemic agents in HCC has begun in earnest. These clinical studies are founded on a growing body of basic and translational science that has identified several potential molecular targets in HCC. The successful development of such targeted agents in the future will be linked to our ability to appropriately select patients for treatment based on their clinical stage (including extent of liver disease and extent of tumor) and on potential predictive markers of response. Here, we review these data in the context of rational drug development in HCC in the front-line setting and in previously treated patients.Clin Cancer Res; 16(2); 390-7.

show abstract

Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): Final report

Cited by 15 publications

References 0 publications

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma

Vascular endothelial growth factor in the management of hepatocellular carcinoma

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

Contact Info

Product

Resources

About